We also present experimental evidence of tumor growth inhibition in patient‐derived xenograft (PDX) models following drug therapy targeting metabolic vulnerabilities downstream of constitutive NRF2 activation in a thyroid SCC harboring NFE2L2, CDKN2A, PIK3CA, and TP53 driver mutations. Here, TP53 is linked to neoplasm.